Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsN/A

The Heart Hive - Cardiomyopathy Study

Sponsor: Imperial College London

NCT ID: NCT04612296

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Health checks and monitoring — no treatment given
Type of study
Observational (no treatment given)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Research genetic analysis (genetic)
How long the study runs
Study runs about 94 months (dates as stated)
About the drug or intervention
Research genetic analysis — genetic: Genetic analysis of DNA extracted from saliva.
Patient visit burden
Not specified by the sponsor
Type of study
Observing health over time
Ages
18 Years and over
Who
All
Number of participants
10,000
Started
2019-11-09
Last checked
2026-03

Plain English Summary

What is this study?

  • • Testing a new treatment for cardiomyopathies
  • • Clinical study - 10,000 participants
  • • This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with cardiomyopathies

Where?

  • • London - Imperial College London

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.

More detail

This study utilises The Heart Hive, an international, online registry of patients with self-reported clinically diagnosed cardiomyopathy or myocarditis, and people with a family history of cardiomyopathy, enrolled on an on-going basis. Registry participants are invited to enter self-reported demographics and health data relevant to their cardiac diagnosis into The Heart Hive online database. Registry participants with self-reported clinically diagnosed cardiomyopathy will be recruited to an observational, prospective study entailing collection of patient-reported baseline demographic data and clinical risk factors, genotyping, and annual collection of follow up data from patients, national registries (NHS England) and medical records. In the pilot phase 100 DCM and 100 HCM patients will be recruited to a validation study. Consent will be sought to access medical information from health care providers in order to compare against and confirm self-reported health information. DNA will be obtained from saliva samples and tested in-house using a panel of clinically validated known Mendelian DCM and HCM genes as a second validation of the accuracy of self-reported diagnosis and to confirm equivalent genetic architecture of DCM and HCM in direct-to-patient recruited cohorts compared to traditional centre of excellence clinic-based recruitments. Following validation of the approach and once funding is in place for genomic studies, larger numbers of cardiomyopathy patients will be recruited to this study from the registry of research willing participants.

CardiomyopathiesMyocarditis

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓Adult (age 18 and over),
  • ✓Males and Females,
  • ✓Capacity to provide agreement to take part,
  • ✓Patients with a confirmed diagnosis of cardiomyopathy or myocarditis,
  • ✓People with a family history of cardiomyopathy confirmed in a first or second degree relative.

Who cannot take part

  • ✗Patients who lack capacity to consent for themselves,
  • ✗Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill).
  • ✗Patients with a confirmed history of coronary artery disease:
  • ✗who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery...
  • ✗who have undergone previous percutaneous coronary intervention or coronary bypass surgery
See the full criteria
Inclusion Criteria: * Adult (age 18 and over), * Males and Females, * Capacity to provide informed consent, * Patients with a confirmed diagnosis of cardiomyopathy or myocarditis, * People with a family history of cardiomyopathy confirmed in a first or second degree relative. Note: Pregnant women are eligible. This study is observational and entirely separate from clinical care. Exclusion criteria: * Patients who lack capacity to consent for themselves, * Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill). * Patients with a confirmed history of coronary artery disease: * who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery disease, or * who have undergone previous percutaneous coronary intervention or coronary bypass surgery * History of primary valvular heart disease or congenital heart disease * Severe, untreated or untreatable hypertension (systolic blood pressures routinely \>180 mm Hg and/or diastolic blood pressures \>120 mm Hg)

Where Is This Study? (1 UK site)

Imperial College London

London, United Kingdom

Recruiting
Site contact (verified)
Rachel Buchan, MScinfo@thehearthive.org

How to Get in Touch

Rachel Buchan, MD PhD

Sponsor contact

CONTACT

0 207 351 8144 info@thehearthive.org
Data sourced from ClinicalTrials.gov · Last verified: 2026-03